GHRP-6 dosage

GHRP-6 oral dosage

Reported-use amounts for GHRP-6 are 0.3 mg/kg, 2x daily, for 4 days.[11]

GHRP-6 is a ghrelin-receptor agonist with GH-release and appetite effects. Appetite stimulation can be a relevant response alongside endocrine activity.[1][2][3][4][11]

GHRP-6 injectable dosage

Reported injectable protocols use 100–300 mcg per administration, 2-3 times daily for 8-12 weeks. An additional reported subcutaneous pattern uses 100–200 mcg per administration one to three times daily for 8–12 weeks. Amount per administration and total daily amount should remain separate when comparing frequencies.[2][3][5][10][6][1][12]

GHRP-6 is a ghrelin-receptor agonist with GH-release and appetite effects. Appetite stimulation can be a relevant response alongside endocrine activity.[2][3][5][4]

GHRP-6 intranasal dosage

Reported-use amounts for GHRP-6 are 0.03 mg/kg, as a single dose.[11]

GHRP-6 is a ghrelin-receptor agonist with GH-release and appetite effects. Appetite stimulation can be a relevant response alongside endocrine activity.[6][2][3][4][11]

GHRP-6 transdermal — ex vivo dissolving microneedles dosage

Dissolving PVA/PVP microneedle arrays carry 75.3 mcg/cm² of GHRP-6 with 800-micrometer needles or 42.8 mcg/cm² with 500-micrometer needles. Release is measured across excised pig skin over 24 hours. These figures describe the peptide loaded onto each skin area, not a measured human absorbed dose.[7][13]

The PVA/PVP arrays dissolve after insertion into the skin sample. Only part of the peptide used during casting remains in the finished microneedles; the initial 2.5 mg casting input is not the final patch payload.[7][2][3][4]

GHRP-6 sublingual dosage

A documented investigational sublingual amount is 30 mcg/kg as a single evening administration. A repeat course is not established, and the endocrine response was limited to a trend rather than a confirmed treatment effect.[6]

GHRP-6 is a ghrelin-receptor agonist with GH-release and appetite effects. Appetite stimulation can be a relevant response alongside endocrine activity.[6][2][3][4]

Frequency and timing

The oral and nasal patterns list pre-meal timing. Injections are commonly timed in the morning, before a workout or before bed. The sublingual exposure is a single evening administration; the experimental transdermal preparation follows its own laboratory schedule.[2][3][5][10][6][1][11][7][13]

Cycle length and breaks

Oral: 4 days. Injectable: 8-12 weeks. Intranasal: Single dose. Transdermal — ex vivo dissolving microneedles: 24-hour release measurement. Sublingual: Single night. A standard break interval between courses is not established.[11][2][3][5][10][6][1][7][13]

Approval and product quality

GHRP-6 is not an FDA-approved drug.[8][9]

Side effects and long-term safety

Hunger, water retention, glucose and IGF-1 changes, and ACTH, cortisol or prolactin effects are relevant to ghrelin-receptor and GH-axis stimulation. Injectable product quality, pregnancy, active malignancy and sports restrictions also require attention.[2][3][5][8][9]

Route-specific dosing limits

Long-term unapproved GH-secretagogue use needs lab monitoring and careful exclusion of higher-risk contexts. Reported-use oral and intranasal schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[2][3][5][8][9][12][11]